[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"h-pylori-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:h-pylori-infection":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,51,76,110,136,157,174,195,216,240,268],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100556749","h-pylori-eradication-with-argon-plasma-during-endoscopy-100556749",false,"NCT06529159","H. Pylori Eradication With Argon Plasma During Endoscopy","H. Pylori Eradication With Argon Plasma During Endoscopy (HEAPE)","HEAPE","Inclusion Criteria:\n\n1. Subjects must be 18 years or older\n2. Confirmed untreated H. pylori infection\n3. Able to understand and sign informed consent\n4. Available to return for all routine follow-up study visits\n5. Patients should have upper endoscopy scheduled according to latest guidelines, e.g., as a part of their diagnostic work-up of HP positive test, regardless of their decision to participate in the study.\n\nExclusion Criteria:\n\n1. Patients actively undergoing H.pylori eradication therapy treatment with antibiotics or proton pump inhibitors (PPIs) two weeks prior to the HEAPE procedure.\n2. Pregnancy or puerperium\n3. Severe cardiopulmonary disease or a history of coronary artery disease (including myocardial infarction within the past 6 months, poorly controlled hypertension, required use of NSAIDs)\n4. Lactation\n5. An inability to provide informed consent\n6. Any other condition which the investigator may deem as an impediment to compliance or hinder completion of the proposed study.\n7. Hernias \u002F aspiration risk","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of the study is to investigate the efficacy and safety of an argon plasma-based therapy - HEAPE - in treating H. pylori infections during endoscopic procedures. By filling the stomach with sodium chloride solution that is treated with APC (PAL), the Investigators hypothesize a significant reduction in H. pylori. The use of PAL instead of direct application of APC allows for a broader and more homogeneous application throughout the stomach and a faster procedure time, as the fluid bypasses the thermal effects typically associated with higher electrical power settings and focuses on the bactericidal action of PAL. It is a procedure that does not involve thermal ablation of the stomach lining. Thus, side effects should be expected to be as low as possible.\n\nTwo different PAL generation modalities will be compared in this study:\n\n1. HEAPE direct: This modality is the direct generation of PAL in the stomach. The stomach is filled with sodium chloride solution which is then treated with APC. With HEAPE direct a potential decrease of reactive species is avoided, as the treatment happens directly at the intended location in the H. pylori infected stomach.\n2. Pre-HEAPE: This modality features the treatment of sodium chloride with APC outside of the patient in a sterile container. After the APC treatment, the generated PAL is administered into the stomach with a syringe through the working channel of the endoscope. Pre-HEAPE allows an easier handling of the APC probe as the treatment of the sodium chloride solution can be done without an endoscope.\n\nTo evaluate the immediate effect of this novel treatment approach the metabolic activity of H. pylori will be assessed using a urea breath test (UBT) before and after treatment. A reduction in H. pylori levels can be detected by a reduction in urease activity in the breath test.\n\nAfter the HEAPE procedure, patients are treated with antibiotics (best practice) as they would be under normal circumstances. Four weeks after treatment, another UBT is performed to determine if H. pylori has been eradicated or if additional antibiotic treatment is indicated.\n\nThis two-arm, randomized, pilot, single-center, prospective clinical study is designed to evaluate the safety, tolerability and proof of concept that PAL has the ability to eradicate or reduce the bacterial load of H. pylori in humans.",[27,28,29,30,31],"Helicobacter Pylori Infection","Helicobacter Pylori","Helicobacter Pylori Gastrointestinal Tract Infection","H. Pylori Infection","H. Pylori Gastrointestinal Disease",[33,34,35,36,37],"Urea Breath Test","Argon Plasma Coagulation (APC)","Endoscopy","Plasma Activated Liquid (PAL)","Plasma Medicine","RECRUITING","2026-02-26",{"date":41,"type":42},"2026-03-02","ACTUAL",{"date":44,"type":42},"2025-07-08",{"date":46,"type":21},"2027-12",{"name":48,"class":49},"Christopher C. Thompson, MD, MSc","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100615486","effect-of-simethicone-on-helicobacter-pylori-detection-in-routine-endoscopy-100615486","NCT07293234","Effect of Simethicone on Helicobacter Pylori Detection in Routine Endoscopy","Effect of Simethicone on Helicobacter Pylori Detection: A Paired, Randomized, Pilot Study in Routine Endoscopic Practice","Inclusion Criteria\n\n* Age ≥18 years and \\\u003C80 years\n* Rapid Urease Test (RUT) positive on endoscopic gastric biopsy\n* Ability to provide informed consent\n\nExclusion Criteria\n\n* Use of antibiotics or bismuth compounds within 4 weeks prior to enrollment\n* Use of proton pump inhibitors (PPIs) within 2 weeks prior to enrollment\n* Use of H2 receptor blockers within 72 hours prior to enrollment\n* History of previous gastric surgery\n* Current anticoagulation therapy\n* Severe thrombocytopenia (platelet count \\\u003C50,000\u002Fmm³)\n* Severe comorbidities that contraindicate the administration of sedation\n* Immunodeficiency\n* Pregnancy\n* Negative initial Rapid Urease Test (RUT)\n* Inability to provide informed consent","19 Years","79 Years",{"count":61,"type":21},100,[24],"Rationale: Although simethicone improves mucosal clarity, in vitro evidence suggests that its surfactant properties may disrupt bacterial adherence or viability. These findings raise concerns that simethicone may negatively affect the sensitivity of endoscopic-based H. pylori diagnostic methods. To date, no prospective in vivo study has evaluated whether simethicone influences H. pylori detection through endoscopic sampling. This randomized paired trial is designed to address this gap in evidence and evaluate whether simethicone administration reduces diagnostic yield.\n\nHypothesis: Simethicone administration prior to upper gastrointestinal endoscopy may reduce the detection rate of H. pylori by interfering with bacterial detection and diagnostic test performance.\n\nNote on Pilot Study Design: This is a pilot study conducted to test feasibility and inform the design of a larger future trial.\n\nObjectives:\n\nTo evaluate whether oral administration of simethicone prior to endoscopy reduces the diagnostic yield of H. pylori using the rapid urease test (RUT).\n\nTo evaluate whether oral administration of simethicone impacts the detection of H. pylori by other diagnostic methods, including histology, PCR, culture, and urea breath testing performed during endoscopy.\n\nTo explore variability in detection methods and determine feasibility for a future larger trial.",[65],"H Pylori Infection","NOT_YET_RECRUITING","2025-12-29",{"date":69,"type":42},"2026-01-02",{"date":71,"type":21},"2026-01",{"date":73,"type":21},"2026-11",{"name":75,"class":49},"Asian Institute of Gastroenterology, India",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100606721","phase-2-efficacy-of-carminal-in-helicobacter-pylori-gastritis-100606721","NCT07179237","Efficacy of Carminal in Helicobacter Pylori Gastritis","Evaluation of the Efficacy of Carminal on the Gastric Mucosa in Patients With Helicobacter Pylori Positive Gastritis","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Patients with clinical symptoms of dyspepsia\n* Patients diagnosed with Helicobacter pylori positive gastritis, confirmed by upper endoscopy with histology\n* Patients who give written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients with peptic ulcer disease\n* Patients with previous gastric surgery\n* Patients with current malignancy or the history of any previous malignancies\n* Patients taking another investigational product, or have taken any investigational product in the last year\n* Patients with known hypersensitivity to any ingredients found in the investigational product.\n* Decompensated intercurrent illnesses, including: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver disease, and psychiatric illnesses that may limit adherence to the requirements of the clinical trial, or any other special condition that, according to the physician's judgement, jeopardises the patient's health or life during participation in the trial.\n* Planned pregnancy for the duration of trial, pregnancy, breast feeding, or postpartum period.\n* Patients with human immunodeficiency virus (HIV).",{"count":84,"type":21},80,[86],"PHASE2","Eighty patients will be included and randomized in two groups, one group (40 patients) will be administered 30 ml of the supplement Carminal, once a day, plus therapy for HP gastitis and the control group (40 patients) will be given standard therapy for HP gastritis with placebo. Treatment will begin after complection of upper endoscopy with histology results from biopted gastric mucosa. Treatment with Carminal will be continued after successful HP eradication during 12 weeks. The final evaluation will take place 12 weeks after the last Carminal intake, when control endoscopy with histology will be performed. The study will last approximately 24 weeks.",[89,65,90,91,92],"H Pylori Gastritis","H Pylori Eradication","Gastritis Associated With Helicobacter Pylori","Gastric Mucosal Lesion",[94,95,96,28,97,98],"Antioxidant","Aloe vera","Food Supplement","Gastritis","Gastric mucosa","2025-09-16",{"date":101,"type":42},"2025-09-17",{"date":103,"type":42},"2025-08-04",{"date":105,"type":21},"2026-10-05",{"name":107,"class":108},"Catalysis SL","INDUSTRY",2,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":17,"minAge":118,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":50},"100468993","screening-strategy-for-gastric-cancer-prevention-100468993","NCT05387005","Screening Strategy for Gastric Cancer Prevention","Identification of the Optimal Screening Strategy for Gastric Cancer Prevention","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Never screened and treated for H. pylori infection\n\nExclusion Criteria:\n\n* Ever undergone gastrectomy\n* Patients with gastric cancer\n* Have been screened or tested for H. pylori infection\n* Ever received H. pylori eradication therapy\n* Have taken proton pump inhibitor within two weeks\n* Have taken antibiotics within two weeks",true,"20 Years",{"count":120,"type":21},4403,[24],"There are still some unsolved questions regarding population-based screening program for H. pylori infection to prevent gastric cancer, such as how to perform the optimal screening strategies. A prospective, randomized trial will be conducted to compare the acceptability, compliance (\u002Fadherence), and accuracy of diagnostic tests in a population-based H. pylori screening and gastric cancer prevention program.\n\nInitially, we planned to recruit 10,000 adults aged ≥20 years who had not previously undergone H. pylori screening or treatment. Eligible participants were to be randomly allocated in a 1:1:1:1 ratio to one of four groups, each receiving a different combination of diagnostic tests. However, a preliminary analysis led to a recalculation of the required sample size. Following the approval of an Institutional Review Board (IRB) amendment, enrollment was discontinued for Group B (HpSA method) and Group D (Two-stage screening method). The final number of participants enrolled in Group B and Group D was 852 and 851, respectively. Groups A (UBT method) and Group C (standard method) will continue to enroll participants through an additional 1:1 randomization until each group reaches a total of 1,350 participants.",[30],[125,126],"H. pylori","screening","2025-08-13",{"date":129,"type":42},"2025-08-17",{"date":131,"type":42},"2022-07-19",{"date":133,"type":21},"2029-04-30",{"name":135,"class":49},"National Taiwan University Hospital",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":50},"100596468","recurrence-of-h-pylori--incidence-and-influential-factors-100596468","NCT07045857","Recurrence of H Pylori : Incidence and Influential Factors.","Recurrence of H Pylori : Incidence and Influential Factors in Sohag Government.","Inclusion Criteria:\n\n* Age: 18-75 years old.\n* H. pylori infection: Confirmed by endoscopy, biopsy, or non-invasive tests (e.g., urea breath test, stool antigen test).\n* Symptoms: Presence of dyspepsia, peptic ulcer disease, or other H. pylori-related symptoms.\n* Laboratory tests: Normal liver and kidney function, and no significant abnormalities in blood counts.\n\nExclusion Criteria:\n\n* Patients receiving eradication therapy in the past taking proton pump inhibitors,, H2 blockers ,,bismuth ,, antibiotics or other medications that interfere with the result of the examination in the recent 4 weeks.\n* Gastrointestinal disorders: Severe gastrointestinal disorders (e.g., gastric cancer, inflammatory bowel disease ,gastric or duodenal ulcer with current or recent bleeding , or clinical significant gastrointestinal bleeding within 4 weeks of randomization).\n* Malignancies: Active or recent malignancies.\n* Severe comorbidities: Unstable or severe comorbidities (e.g., heart failure, liver cirrhosis).","75 Years",{"count":61,"type":21},[24],"This study aims to determine recurrence rates, identify influential factors, investigate key factors that contribute to recurrence, evaluate treatment effectiveness and to assess the efficacy of different eradication regimens and their role in reducing recurrence.",[30],"2025-06-23",{"date":150,"type":42},"2025-07-01",{"date":152,"type":42},"2025-05-13",{"date":154,"type":21},"2025-11-20",{"name":156,"class":49},"Sohag University",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":171,"leadSponsor":173,"locationsCount":50},"100596456","efficacy-of-vonoprazan-based-dual-and-triple-therapy-for-patient-with-helicobacter-pylori-infection-100596456","NCT07045688","Efficacy of Vonoprazan Based Dual and Triple Therapy for Patient With Helicobacter Pylori Infection","Efficacy of Vonoprazan Based Dual and Triple Therapy for Naive Patient With Helicobacter Pylori Infection","Inclusion Criteria:\n\n* Age: \\>18 years old.\n* H. pylori infection: Confirmed by histopathology or non-invasive tests (e.g., stool antigen test).\n\nExclusion Criteria:\n\n* Prior H. pylori treatment: Previous treatment for H. pylori infection.\n* Allergies: Known allergies to study medications or components.\n* Patients cannot finish treatment course.\n* Patient missed follow up.\n* Patients refusing or neglecting test of cure for H. pylori.",{"count":165,"type":21},150,[24],"This study aims to assess Efficacy of vonoprazan based dual and triple therapy for naïve patient with Helicopacter Pylori infection in Sohag Government .",[30],{"date":150,"type":42},{"date":152,"type":42},{"date":172,"type":21},"2025-11-25",{"name":156,"class":49},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":50},"100593926","efficacy-analysis-of-saccharomyces-boulardii-combined-with-minocycline-in-treatment-nave-patients-with-helicobacter-pylori-infection-100593926","NCT07012785","Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection","Inclusion Criteria:\n\n1. Aged 18-70 years, regardless of gender;\n2. Positive 13C\u002F14C urea breath test result;\n3. No previous history of H. pylori eradication treatment;\n4. Agreement to participate in this study and signing of the informed consent form.\n\nExclusion Criteria:\n\n1. History of ≥ 1 instance of failed H. pylori eradication;\n2. Use of antibiotics (including antibacterial traditional Chinese medicines), nonsteroidal anti-inflammatory drugs (NSAIDS), bismuth agents, H2 receptor antagonists (H2RAs), proton-pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CAB) within 4 weeks before treatment;\n3. Plans to conceive, pregnancy, or breastfeeding;\n4. Severe liver, kidney, or cardiovascular diseases; malignancies; and alcoholism;\n5. Allergies to the drugs used in this study or a history of penicillin allergy;\n6. The inability to correctly express one's symptoms and wishes, such as inability due to mental illness or severe neurosis.","70 Years",{"count":182,"type":21},208,[24],"To assess the efficacy and safety of Saccharomyces boulardii combined with triple therapy containing minocycline in the initial eradication of Helicobacter pylori (H. pylori) infection",[30],"2025-06-02",{"date":188,"type":42},"2025-06-10",{"date":190,"type":21},"2025-06",{"date":192,"type":21},"2025-12",{"name":194,"class":49},"Zhongda Hospital",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100234309","european-registry-on-the-management-of-helicobacter-pylori-infection-100234309","NCT02328131","European Registry on the Management of Helicobacter Pylori Infection","Inclusion Criteria:\n\n* Infected adult patients by Helicobacter pylori\n\nExclusion Criteria:",{"count":202,"type":21},10000,"OBSERVATIONAL","The great diversity of regimens and treatment lines, the different efficacy of these, mostly due to the increase in bacterial antibiotic resistance and regional differences, requires a continuous critical analysis of clinical practice, evaluating systematically the efficacy and safety of the different regimens and the cost-effectiveness of the different diagnostic-therapeutic strategies. This will help in the design of an efficient and optimized treatment that will reduce number of re-treatments, diagnostic tests and the appearance of associated pathologies such as peptic ulcers, gastrointestinal bleeding and, probably, gastric cancers. Therefore, the evaluation of real clinical practice using non-interventionist registries will help to improve the design and organization of European Consensus on the management of H. pylori infection, which is the best way to establish healthcare efficiency.\n\nPrimary aim\n\nTo obtain a database registering systematically over a year a large and representative sample of routine clinical practice of European gastroenterologists in order to produce descriptive studies of the management of H. pylori infection.\n\nSecondary aims\n\n1. To evaluate H. pylori infection consensus and clinical guidelines implementation in different countries.\n2. To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori.\n3. To evaluate accessibility to healthcare technologies and drugs used in the management of H. pylori infection.\n4. To allow the development of partial and specific analysis by the participating researchers after approval by the Registry's Scientific Committee\n\nMethodology Non-interventionist prospective multicentre international registry promoted by the European Helicobacter Study Group. A renowned gastroenterologist from each country was selected as Local Coordinator (30 countries). They will in turn select up to ten gastroenterologists per country that will register the routine clinical practice consultations they receive over 10 years in an electronic Case Report Form (e-CRF). Variables retrieved will include clinical, diagnostic, treatment, eradication confirmation and outcome data. The database will allow researchers to perform specific subanalysis after approval by the Scientific Committee of the study.",[30],"2024-10-01",{"date":208,"type":42},"2024-10-02",{"date":210,"type":4},"2013-06",{"date":212,"type":21},"2034-12",{"name":214,"class":49},"Javier P. Gisbert",30,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":225,"studyType":203,"phases":4,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":50},"100560608","argentinean-registry-on-the-management-of-helicobacter-pylori-infection-100560608","NCT06579365","Argentinean Registry on the Management of Helicobacter Pylori Infection","ArgReg-Hp","Inclusion Criteria:\n\nInfected adult patients by Helicobacter pylori\n\n\\-\n\nExclusion Criteria:\n\nPregnant or lactating women Subjects currently taking any antibiotics Administration of antibiotics or bismuth in the preceding 4 weeks or PPI 2 weeks previous Unable or refuse to give consent",{"count":224,"type":21},5000,"3 Months","Helicobacter pylori (H pylori) is the main cause of chronic gastritis and peptic ulcer disease. In addition, is the main risk factor for gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. It is estimated that around 50% of the Argentinean population is infected with H pylori. The optimal management of H pylori remains unclear. In Argentina, most treatments are prescribed on an empiric basis, unaware of the bacterial antibiotic resistance profile.\n\nMeta-analysis showed that susceptibility-guided treatment is not better than empirical treatment in first and second line treatment therapy if the most effective local regimens are prescribed. Updated information concerning local data is needed to design the best strategy to treat H pylori infection in order to reach high eradication rates and to introduce the principles of antimicrobial stewardship to reduce inappropriate antibiotic use.\n\nThe Argentinean Registry on H pylori (ArgReg-Hp) management was launched in May 2021 in order to obtain a large and representative sample of routine clinical practice of Argentinean gastroenterologist. Its main focus was to identify therapies that are highly effective and can be used empirically. Test of cure data is a surrogate method for susceptibility testing and resistance Primary aim To obtain a database registering systematically of a large and representative sample of routine clinical practice of Argentinean gastroenterologists in order to produce descriptive studies of the management of H. pylori infection.\n\nSecondary aims To perform studies focused on epidemiology, efficacy and safety of the commonly used treatments to eradicate H. pylori.\n\nThe Argentinean Registry on H pylori management is a National , multicenter, prospective, non interventional registry recording data on H pylori management since May 2021. The ArgReg-Hp is promoted by Instituto de Investigaciones Médicas Alfredo Lanari (IDIM), Universidad de Buenos Aires and Club Argentino Estómago y duodeno (CADED).\n\nEthics: ArgReg-Hp was approved by the Ethics Committee IDIM, University of Buenos Aires as the reference IRB, and was approved by each center participant",[228,65],"H.Pylori Gastrointestinal Disease",[230],"H pylori","2024-08-27",{"date":233,"type":42},"2024-08-30",{"date":235,"type":42},"2021-05-17",{"date":237,"type":21},"2034-01-01",{"name":239,"class":49},"University of Buenos Aires",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":117,"sex":17,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100537236","h-pylori-screen-and-treat-study-in-a-population-of-young-adults-100537236","NCT06275204","H. Pylori Screen-and-treat Study in a Population of Young Adults","Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults","Inclusion Criteria:\n\n* Young adults (generally 30 - 34 years of age)\n\nExclusion Criteria:\n\n* Patients with mental or developmental limitations who cannot provide a fully-informed consent to participate (based on the assessment from research or patient's personal physician team)\n* Previously treated H. pylori infection\n* History of partial or total gastric resection due to benign or malign lesions","30 Years","34 Years",{"count":250,"type":21},6800,"Gastric cancer remains a major challenge to public health on a global scale. H. pylori related cancer burden contributes to the largest proportion of cancer cases attributable to infections in Europe. Considering its absolute burden and persisting disparities, in addition to the substantial prevalence of H. pylori infection worldwide that is treatable, gastric cancer is a logical target for urgent action for prevention. Population-based H. pylori test-and-treat has therefore been proposed as a strategy for gastric cancer prevention. To fill the gaps in knowledge about gastric cancer prevention through H. pylori screening and eradication in younger adults, a study of a population-based H. pylori test-and-treat strategy in Ireland, Croatia, Latvia, Poland, Romania and Slovenia.\n\nMain goals of this study are to assess future program processes, feasibility, acceptability and effectiveness. In total of 6,800 adults aged 30-34 will be tested for H. pylori infection. They will be randomly selected to represent the chosen population and invited to participate in the study based on informed consent. Confirmed infections will be treated by available combined therapy in line with treatment guidelines and the success of eradication will be retested during a control check-up.\n\nPatients who will provide their consent to participate will undertake an interview about the risk factors in early childhood and their habits regarding alcohol consumption and use of tobacco. Compliance to testing and treatment, treatment results, adverse effects and reasons for dropping out will be additionally monitored. Gathered data will be analysed in alignment with our research questions. The investigators will disseminate reports and present the results to both the general public and the scientific community in order to foster future developments in gastric cancer prevention.",[253,65,90,254],"Gastric Cancer","H-pylori",[125,256,257,126],"gastric cancer","eradication therapy","2024-03-03",{"date":260,"type":42},"2024-03-05",{"date":262,"type":21},"2024-03-04",{"date":264,"type":21},"2026-12-01",{"name":266,"class":49},"University of Latvia",7,{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":118,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":50},"100417283","phase-4-comparison-of-vonoprazan-based-versus-lansoprazole-based-triple-therapy-high-dose-dual-therapy-bismuth-and-non-bismuth-quadruple-therapy-in-the-first-line-treatment-of-helicobacter-pylori-infection-100417283","NCT04713670","Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection","Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection - a Multicenter, Open Labelled, Randomized Pilot Trial","Inclusion Criteria:\n\n1. Patients with naive H. pylori infection\n2. Subjects with over 20 years old\n\nExclusion Criteria:\n\n1. Younger than 20 years old\n2. Ever received H. eradication therapy\n3. ever received total or subtotal gastrectomy in the past\n4. Severe chronic disease, such as end stage renal disease, liver cirrhosis, incurable malignant tumors\n5. Women who are pregnant or breastfeeding\n6. Those who are not suitable to receive study drugs: such as a history of allergies to study drugs or serious side effects, etc.\n7. Patients with chronic hepatitis (AST or ALT \\>40 IU\u002FL)\n8. Subjects who cannot sign informed consent by themselves",{"count":276,"type":21},1200,[278],"PHASE4","Background: Bismuth quadruple therapy is currently the recommended first-line regimen for Helicobacter pylori (H. pylori) infection in regions with high clarithromycin resistance. Recent randomized trials showed that 7-day vonoprazan-based triple therapy is superior to 7-day lansoprazole-based triple therapy in Japanese. A recent trial further showed that 7-day vonoprazan-based high dose amoxicillin dual therapy was non-inferior to 7-day vonoprazan-based triple therapy in Japanese. However, whether vonoprazan based dual, triple, and quadruple therapies are superior or non-inferior to lansoprazole based triple or quadruple therapy remains unknown.\n\nObjective: The investigators aimed to compare the efficacy and safety of 14-day vonoprazan-based dual therapy, triple therapy, bismuth quadruple therapy, reverse hybrid therapy, and lansoprazole-based bismuth quadruple therapy and triple therapy in the first-line treatment of H. pylori infection in this pilot study.\n\nMethods: Using a block randomization with a block size of 16 in a 1:1 ratio, 1200 eligible adult subjects aged 20 years or greater with at least two positive tests for H. pylori infection will be randomized to receive one of the following regimens: (A) vonoprazan-based triple therapy for 14 days (T-V14): vonoprazan 20mg twice daily, clarithromycin-XL 500mg twice daily, amoxicillin 1000mg twice daily for 14 days ; or (B) vonoprazan-based triple therapy for 7 days (T-V7): vonoprazan 20mg twice daily, clarithromycin-XL 500mg twice daily, amoxicillin 1000mg twice daily for 7 days ; or (C): vonoprazan-based dual therapy for 14 days (D-V14): vonoprazan 20mg twice daily, amoxicillin 750mg every 8 hour for 14 days; (D): vonoprazan-based high dose dual therapy for 14 days (HD-V14): vonoprazan 20mg twice daily, amoxicillin 750mg four times a day for 14 days; or (E) vonoprazan-based bismuth quadruple therapy for 14 days (BQ-V14) vonoprazan 20mg twice daily, bismuth tripotassium dicitrate 300 mg three times a day, tetracycline 500mg three times a day, and metronidazole 500mg three times a day for 14 days; or (F) vonoprazan-based reverse hybrid therapy for 14 days (RH-V14): vonoprazan 20mg twice daily, and amoxicillin 1000mg twice daily for 14 days, plus clarithromycin-XL 500mg twice daily and metronidazole 500mg twice daily for the first 7 days ; or (G) lansoprazole-based bismuth quadruple therapy for 14 days (BQ-L14) lansoprazole 30mg twice daily, bismuth tripotassium dicitrate 300 mg three times a day, tetracycline 500mg three times a day, and metronidazole 500mg three times a day for 14 days; or (H) lansoprazole-based triple therapy for 14 days (T-L14): lansoprazole 30mg twice daily, clarithromycin-XL 500mg twice daily, amoxicillin 1000mg twice daily for 14 days. Subjects who fail after first-line therapy will be randomized to receive either vonoprazan-based levofloxacin triple therapy (LT-V14) containing vonoprazan 20mg twice daily, levofloxacin 250mg twice daily, and amoxicillin 1000mg twice daily for 14 days or vonoprazan-based levofloxacin reverse hybrid therapy (LRH-V14) containing vonoprazan 20mg twice daily, and amoxicillin 1000mg twice daily for 14 days, plus levofloxacin 250mg twice daily and metronidazole 500mg twice daily for the first 7 days. The minimum inhibitory concentrations will be determined by agar dilution test. 23S ribosomal RNA and gyrase A mutations will be determined by PCR methods followed by direct sequencing in a subgroup of patients. The TWB2.0 SNP array will be used for genotyping of genome wide single nucleotide polymorphism.\n\nOutcome analysis: The primary outcome is the eradication rate in the first-line treatment. The secondary outcomes are the compliance, frequency of adverse events, the overall eradication rate after two treatments.",[30],[282,283,284,285,286,287],"H.pylori","vonoprazan","lansoprazole","triple therapy","high dose dual therapy","bismuth quadruple","2023-03-06",{"date":290,"type":42},"2023-03-08",{"date":292,"type":42},"2021-03-10",{"date":294,"type":21},"2026-12",{"name":135,"class":49}]